SUVN Study

Study Type

Cognitive Impairment & Alzheimer's Disease

Study Purpose

The SUVN research study will evaluate a study drug and its effect on patients living with moderate Alzheimer's disease. The study will assess the improvement of patients' ability to perform daily living activities and cognitive function over time. Researchers will also evaluate the drug's safety and how well participants tolerate the medication. The effects of the drug versus a placebo will be measured in subjects currently receiving stable doses of donepenzil and memantine therapy.

About the Study

Study participants and their partners/caregivers will undergo a series of visits to Pennington Biomedical for assessment and observation. 

Members of the study team will remain in contact with participants throughout the study to ensure they are taking the medication as instructed, as well as to discuss any reactions to the drug.

Study Design

Total number of visits required for participants in this study:

  • Up to 3 screening visits
  • 5 study visits

Study Procedures:

  • Health assessment/vital signs (blood pressure, pulse, etc.)
  • Medical history
  • Questionnaires
  • Physical and neurological examinations
  • Test for heart health (ECG)
  • Imaging (MRI)
  • Blood tests
  • Urine collection

Study Qualifications

To qualify, participants in this study should:

  • Be between the ages of 50-85 years old.
  • Have a diagnosis of probable Alzheimer's disease.  
  • Be on a stable dose of donepezil hydrochloride and memantine hydrochloride for at least 3 months prior to enrolling in this study.
  • Have a trial partner/caregiver to attend all study visits with the participant and be able to answer questions about the participant.

Study Duration

Participation in this study will last approximately 8 months.


Compensation of up to $150 is offered for the completion of this study.

Study Contact

Interested volunteers may call 225-763-2973 or email


English Calculation
Enter Your Weight: 
Enter Your Height: 
 ft.  in.
Your BMI: